SK286020B6 - Použitie N-benzazepínových derivátov kyseliny octovej na profylaxiu a/alebo liečenie poškodenia srdca a výrobky s obsahom týchto derivátov - Google Patents

Použitie N-benzazepínových derivátov kyseliny octovej na profylaxiu a/alebo liečenie poškodenia srdca a výrobky s obsahom týchto derivátov Download PDF

Info

Publication number: SK286020B6
Authority: SK; Slovakia
Prior art keywords: group; formula; alkyl; phenyl; compounds
Prior art date: 1999-07-13

Application number

SK14-2002A

Other languages

English (en)

Slovak (sk)

Other versions

SK142002A3 (en

Inventor

Susanna Rozsa

Julius Gy. Papp

Dirk Thorm�Hlen

Harald Waldeck

Original Assignee

Solvay Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-13

Filing date

2000-07-10

Publication date

2008-01-07

2000-07-10 Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh

2002-06-04 Publication of SK142002A3 publication Critical patent/SK142002A3/sk

2008-01-07 Publication of SK286020B6 publication Critical patent/SK286020B6/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 20
238000011321 prophylaxis Methods 0.000 title claims abstract description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title abstract description 16
150000001875 compounds Chemical class 0.000 claims abstract description 37
150000003839 salts Chemical class 0.000 claims abstract description 19
239000000824 cytostatic agent Substances 0.000 claims abstract description 16
230000001085 cytostatic effect Effects 0.000 claims abstract description 16
231100000457 cardiotoxic Toxicity 0.000 claims abstract description 14
230000001451 cardiotoxic effect Effects 0.000 claims abstract description 14
229940045799 anthracyclines and related substance Drugs 0.000 claims abstract description 13
239000003242 anti bacterial agent Substances 0.000 claims abstract description 10
229940088710 antibiotic agent Drugs 0.000 claims abstract description 9
230000003115 biocidal effect Effects 0.000 claims abstract description 9
229960001156 mitoxantrone Drugs 0.000 claims abstract description 9
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 9
238000002560 therapeutic procedure Methods 0.000 claims abstract description 8
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 82
125000000217 alkyl group Chemical group 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
-1 dioxolanylmethyl Chemical group 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 11
230000003683 cardiac damage Effects 0.000 claims description 10
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 10
150000007513 acids Chemical class 0.000 claims description 7
230000003319 supportive effect Effects 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 6
238000002512 chemotherapy Methods 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 4
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
229960000975 daunorubicin Drugs 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
229960004679 doxorubicin Drugs 0.000 claims description 3
229960001904 epirubicin Drugs 0.000 claims description 3
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
229960000641 zorubicin Drugs 0.000 claims description 2
FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims 1
230000002107 myocardial effect Effects 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
238000004519 manufacturing process Methods 0.000 abstract 1
229940009456 adriamycin Drugs 0.000 description 38
239000000126 substance Substances 0.000 description 35
241001465754 Metazoa Species 0.000 description 32
239000003814 drug Substances 0.000 description 20
230000000694 effects Effects 0.000 description 14
229940079593 drug Drugs 0.000 description 13
238000000034 method Methods 0.000 description 13
239000000902 placebo Substances 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 9
230000001590 oxidative effect Effects 0.000 description 8
230000037396 body weight Effects 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000003078 antioxidant effect Effects 0.000 description 6
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
229960002591 hydroxyproline Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
206010048610 Cardiotoxicity Diseases 0.000 description 5
231100000259 cardiotoxicity Toxicity 0.000 description 5
210000004165 myocardium Anatomy 0.000 description 5
239000003826 tablet Substances 0.000 description 5
241000124008 Mammalia Species 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
229940087168 alpha tocopherol Drugs 0.000 description 4
150000001991 dicarboxylic acids Chemical class 0.000 description 4
229960000984 tocofersolan Drugs 0.000 description 4
235000004835 α-tocopherol Nutrition 0.000 description 4
239000002076 α-tocopherol Substances 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
125000005042 acyloxymethyl group Chemical group 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000002340 cardiotoxin Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
125000004043 oxo group Chemical group O=* 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010007572 Cardiac hypertrophy Diseases 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
206010061592 cardiac fibrillation Diseases 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000002600 fibrillogenic effect Effects 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010028293 Muscle contractions involuntary Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241001415849 Strigiformes Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005428 food component Substances 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940118019 malondialdehyde Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
238000009519 pharmacological trial Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Immunology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK14-2002A 1999-07-13 2000-07-10 Použitie N-benzazepínových derivátov kyseliny octovej na profylaxiu a/alebo liečenie poškodenia srdca a výrobky s obsahom týchto derivátov SK286020B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19932555A DE19932555A1 (de)	1999-07-13	1999-07-13	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
PCT/EP2000/006525 WO2001003699A1 (de)	1999-07-13	2000-07-10	Arzneimittel mit protektiver wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische substanzen

Publications (2)

Publication Number	Publication Date
SK142002A3 SK142002A3 (en)	2002-06-04
SK286020B6 true SK286020B6 (sk)	2008-01-07

Family

ID=7914519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK14-2002A SK286020B6 (sk)	1999-07-13	2000-07-10	Použitie N-benzazepínových derivátov kyseliny octovej na profylaxiu a/alebo liečenie poškodenia srdca a výrobky s obsahom týchto derivátov

Country Status (28)

Country	Link
US (1)	US6906059B2 (es)
EP (1)	EP1200095B1 (es)
JP (1)	JP4824235B2 (es)
KR (1)	KR100738940B1 (es)
CN (1)	CN1267099C (es)
AR (1)	AR024476A1 (es)
AT (1)	ATE306926T1 (es)
AU (1)	AU782733B2 (es)
BR (1)	BR0012442A (es)
CA (1)	CA2377904C (es)
CZ (1)	CZ299070B6 (es)
DE (2)	DE19932555A1 (es)
DK (1)	DK1200095T3 (es)
ES (1)	ES2246874T3 (es)
HK (1)	HK1049116B (es)
HU (1)	HUP0202424A3 (es)
IL (2)	IL147604A0 (es)
MX (1)	MXPA02000411A (es)
NO (1)	NO329558B1 (es)
NZ (1)	NZ517130A (es)
PL (1)	PL198723B1 (es)
RU (1)	RU2268727C2 (es)
SK (1)	SK286020B6 (es)
TR (1)	TR200200053T2 (es)
TW (1)	TWI280880B (es)
UA (1)	UA73134C2 (es)
WO (1)	WO2001003699A1 (es)
ZA (1)	ZA200200265B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
JP2004536063A (ja) *	2001-05-18	2004-12-02	ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング	医薬の製造における組み合わせたｎｅｐ／ｍｐ−抑制活性を有する化合物の使用
EP1448567B1 (en) *	2001-09-10	2009-12-30	Tibotec Pharmaceuticals	Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CN100591689C (zh) *	2002-01-16	2010-02-24	索尔瓦药物有限公司	苯并氮杂环庚三烯化合物的固体盐及其在制备药物化合物中的应用
AR038681A1 (es) *	2002-02-14	2005-01-26	Solvay Pharm Bv	Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
JP4824573B2 (ja)	2003-11-18	2011-11-30	ゾルファイファーマスーティカルズゲゼルシャフトミットベシュレンクテルハフツング	腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US20050267124A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) *	2004-06-23	2005-12-29	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1827448A1 (en)	2004-12-15	2007-09-05	Solvay Pharmaceuticals GmbH	Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) *	2005-02-18	2006-09-14	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
NZ571465A (en) *	2006-02-27	2011-09-30	Targeted Molecular Diagnostics Llc	Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
WO2007102171A2 (en) *	2006-03-07	2007-09-13	Panacea Biotec Ltd	Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) *	2006-06-16	2007-12-20	Gorissen Henricus R	Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) *	2006-06-22	2007-12-27	Rajesh Jain	Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2850078A1 (de) *	1978-11-18	1980-05-29	Basf Ag	Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahydro-1h-1- benzazepin-2-ons
ES2198418T3 (es) *	1993-07-21	2004-02-01	Yamanouchi Pharmaceutical Co. Ltd.	Derivado de la benzazepina de fusion y composicion farmaceutica que incluye este derivado.
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) *	1996-09-18	1998-03-19	Solvay Pharm Gmbh	Die gastrointestinale Durchblutung fördernde Arzneimittel
US6544979B1 (en) *	1997-09-18	2003-04-08	Janssen Pharmaceuticals, N.V.	Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
DE19906310A1 (de) *	1999-02-16	2000-08-17	Solvay Pharm Gmbh	Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

1999
- 1999-07-13 DE DE19932555A patent/DE19932555A1/de not_active Withdrawn
2000
- 2000-06-23 AR ARP000103183A patent/AR024476A1/es unknown
- 2000-07-05 TW TW089113263A patent/TWI280880B/zh active
- 2000-07-10 NZ NZ517130A patent/NZ517130A/en not_active IP Right Cessation
- 2000-07-10 BR BR0012442-7A patent/BR0012442A/pt not_active Application Discontinuation
- 2000-07-10 HU HU0202424A patent/HUP0202424A3/hu not_active Application Discontinuation
- 2000-07-10 CA CA002377904A patent/CA2377904C/en not_active Expired - Fee Related
- 2000-07-10 TR TR2002/00053T patent/TR200200053T2/xx unknown
- 2000-07-10 DE DE50011388T patent/DE50011388D1/de not_active Expired - Lifetime
- 2000-07-10 JP JP2001508979A patent/JP4824235B2/ja not_active Expired - Fee Related
- 2000-07-10 AT AT00947960T patent/ATE306926T1/de active
- 2000-07-10 KR KR1020027000361A patent/KR100738940B1/ko not_active Expired - Fee Related
- 2000-07-10 PL PL353012A patent/PL198723B1/pl not_active IP Right Cessation
- 2000-07-10 ES ES00947960T patent/ES2246874T3/es not_active Expired - Lifetime
- 2000-07-10 MX MXPA02000411A patent/MXPA02000411A/es active IP Right Grant
- 2000-07-10 HK HK03101159.2A patent/HK1049116B/zh not_active IP Right Cessation
- 2000-07-10 CZ CZ20020052A patent/CZ299070B6/cs not_active IP Right Cessation
- 2000-07-10 IL IL14760400A patent/IL147604A0/xx active IP Right Grant
- 2000-07-10 RU RU2002102709/15A patent/RU2268727C2/ru not_active IP Right Cessation
- 2000-07-10 CN CNB008102015A patent/CN1267099C/zh not_active Expired - Fee Related
- 2000-07-10 AU AU61572/00A patent/AU782733B2/en not_active Ceased
- 2000-07-10 WO PCT/EP2000/006525 patent/WO2001003699A1/de not_active Ceased
- 2000-07-10 SK SK14-2002A patent/SK286020B6/sk not_active IP Right Cessation
- 2000-07-10 DK DK00947960T patent/DK1200095T3/da active
- 2000-07-10 EP EP00947960A patent/EP1200095B1/de not_active Expired - Lifetime
- 2000-10-07 UA UA2002021058A patent/UA73134C2/uk unknown
2002
- 2002-01-11 ZA ZA200200265A patent/ZA200200265B/xx unknown
- 2002-01-11 NO NO20020132A patent/NO329558B1/no not_active IP Right Cessation
- 2002-01-13 IL IL147604A patent/IL147604A/en not_active IP Right Cessation
- 2002-01-14 US US10/043,268 patent/US6906059B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO329558B1 (no)	2010-11-15
HK1049116B (zh)	2006-12-08
CA2377904A1 (en)	2001-01-18
ATE306926T1 (de)	2005-11-15
NO20020132L (no)	2002-03-12
SK142002A3 (en)	2002-06-04
EP1200095A1 (de)	2002-05-02
DE19932555A1 (de)	2001-01-18
IL147604A0 (en)	2002-08-14
DK1200095T3 (da)	2005-11-14
RU2268727C2 (ru)	2006-01-27
AU6157200A (en)	2001-01-30
IL147604A (en)	2006-12-31
NZ517130A (en)	2004-10-29
TR200200053T2 (tr)	2002-05-21
ES2246874T3 (es)	2006-03-01
NO20020132D0 (no)	2002-01-11
US20030040512A1 (en)	2003-02-27
TWI280880B (en)	2007-05-11
WO2001003699A1 (de)	2001-01-18
CN1373666A (zh)	2002-10-09
DE50011388D1 (de)	2006-03-02
JP4824235B2 (ja)	2011-11-30
US6906059B2 (en)	2005-06-14
PL353012A1 (en)	2003-10-06
ZA200200265B (en)	2003-03-26
CN1267099C (zh)	2006-08-02
AU782733B2 (en)	2005-08-25
PL198723B1 (pl)	2008-07-31
UA73134C2 (en)	2005-06-15
CZ200252A3 (cs)	2002-08-14
AR024476A1 (es)	2002-10-02
MXPA02000411A (es)	2002-07-02
HUP0202424A2 (hu)	2002-11-28
KR100738940B1 (ko)	2007-07-12
HUP0202424A3 (en)	2003-03-28
JP2003504336A (ja)	2003-02-04
BR0012442A (pt)	2002-04-02
HK1049116A1 (en)	2003-05-02
CZ299070B6 (cs)	2008-04-16
KR20020019514A (ko)	2002-03-12
EP1200095B1 (de)	2005-10-19
CA2377904C (en)	2009-03-24

Publication	Publication Date	Title
SK286020B6 (sk)	2008-01-07	Použitie N-benzazepínových derivátov kyseliny octovej na profylaxiu a/alebo liečenie poškodenia srdca a výrobky s obsahom týchto derivátov
CA1165689A (en)	1984-04-17	Method of increasing oral absorption of polar bioactive agents
US6573292B1 (en)	2003-06-03	Methods and compositions for the treatment of chronic lymphocytic leukemia
JP2002537258A5 (es)	2011-08-25
EP0786993B1 (en)	2002-06-05	Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders
RU2005102110A (ru)	2005-09-20	Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
EP0781128B1 (en)	2005-11-23	Clotrimazole metabolites in the treatment of sickle cell disease
US20020002202A1 (en)	2002-01-03	Use of fumarate salt of L-carnitine or its alkanoyl derivatives in ischaemia
US3821381A (en)	1974-06-28	Method of treatment
EP1391203A1 (en)	2004-02-25	Antitumor agents
US3749781A (en)	1973-07-31	Pharmaceutical composition and method of treatment
US3821409A (en)	1974-06-28	Method of treatment
WO1984004246A1 (en)	1984-11-08	Oncolytic drug combinations
EP1671631A2 (en)	2006-06-21	Compositions for the treatment of chronic lymphocytic leukemia
IE54373B1 (en)	1989-09-13	Pharmaceutical compositions comprising, 7,8-dihydroxy-1(hydroxyphenyl)-2,3,4,5-tetrahydro-ih-3-benzanepine derivatives and a beta-adrenergic blocking compound

Legal Events

Date	Code	Title	Description
2013-04-03	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20120710